

Fall Group Meeting

Chicago Specials

SEPTEMBER 18-20, 2025

Lung Committee

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS
 Scientific Leadership
 Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgil, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD
 Designates
 Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN
 Patient Advocate: Judy Johnson, MBA

Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraichi, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Friday, September 19, 2025 11:30 a.m. - 1:30 p.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

11:30 - 11:45 am General Update & Accruals: Jhanelle E. Gray, MD

11:45 - 11:50 am Patient Advocate Update: Judy Johnson, MBA

11:50 - 11:55 am Thoracic Surgery Session: Eric Toloza, MD, PhD

11:55 - 12:00 pm Thoracic Radiation Session: Megan Daly, MD

12:00 - 12:05 pm Translational Medicine Session: Philip C. Mack, PhD

12:05 - 12:10 pm Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN

12:10 - 12:25 pm Keynote Speaker - Paul Bunn, MD, Distinguished Professor of Medical Oncology, James Dudley Chair of Cancer Research, University of Colorado

12:25 - 12:55 pm Thoracic Medical Oncology: Jhanelle Gray, MD

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 2. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

S2409 PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC). Anne Chiang, MD, PhD and Alberto Chiappori

CTIU2317/S2402 "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)". Activated: 12/11/24; Accrual Goal: 1100. Raid Aljumaily, MD and Raymond Osarogiagbon, MD

Lung Committee

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Activated: 6/15/20; Accrual Goal: 47; Accrual: 45. Raid Aljumaily, MD

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Activated: 1/10/20; Accrual Goal: 668; Accrual: 286. Chad Rusthoven, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3693. Karen Reckamp, MD and David R. Gandara, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Activated: 4/28/25; Accrual Goal: 378; Accrual: 164. Saiama Waqar, MD, MSCI (NRG) and Dr. Tina Li (SWOG)

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)". Activated: 9/27/24; Accrual goal: 88; Accrual: 12. Shirish Gadgeel, MD and Christian Rolfo, MD

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)". Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 31. Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 19. Paul Paik, MD (ECOG-ACRIN) and Xiuning Le, MD, PhD (SWOG)

12:55 - 1:30 pm **Open Discussion**

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel. Activation: 9/27/24.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li. Activation: 4/28/25.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2414, "A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

Lung Committee

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and

Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone

Lung Committee

for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Scott and Riess.

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1800G, "A Randomized Phase II Study of Casdozokitug with or without Toripalimab in Participants with Previously Treated Relapsed or Refractory Advanced Lung Squamous Cell Carcinoma (NRG Lung-MAP Non-match Sub-Study)." Drs. Henick and Marron.

S1900P, "A Phase II Study of Sapanisertib Plus Serabelisib Plus Paclitaxel Versus Standard of Care Chemotherapy in Participants with NFE2L2, KEAP1 or PI3K Pathway-Positive Stage IV Squamous Cell Lung Cancers (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Paik and Riano.

S2409, "PRISM: Precision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)" Drs. Chiang, Chiappori, Kim, et al.

Clinical Trials Partnerships (CTP)

Developing Studies

21CTP. HN01, CAPT-HN, "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

Lung-MAP Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study. Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR. *Clinical Cancer Research* Jun 4. doi: 10.1158/1078-0432.CCR-24-3658. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/40465842/>

Submitted Manuscripts

S1900A S1900A: SQUAMOUS: A phase II study of rucaparib in patients with LOH-positive stage IV NSCLC (Lung-MAP Biomarker-driven sub-study). Homologous Recombination Deficiency (HRD) Phenotypes of non-small cell lung cancer (NSCLC) that are potentially actionable to PARP inhibition identified in Lung-MAP substudy S1900A. Riess J, Miao J, Wheatley-Price P, Reckamp K, Redman M, Kozono D, Edelman M; Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Sokol E, Schrock A, Madison R, Jin D, Wang S, Waqar S, Stinchcombe T, Borghaei H, Gray J, Herbst R, Gandara D, Kelly K. Submitted, 2025.

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted.

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302
Moffitt Cancer Center	18	-	1	1	1	-	-	-	-	52
Montana Cancer Consortium NCORP	9	-	1	1	-	-	-	1	1	1
Mount Sinai Hospital	-	-	-	-	-	-	-	9	-	2
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	3
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	1	-	-	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	104	-	1	2	-	-	-	8	1	3
Northwell Health NCORP	-	-	-	-	-	-	-	1	-	-
Northwestern University LAPS	27	-	1	-	1	-	-	-	-	18
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	6
Oregon Health and Science University	13	-	-	-	1	-	1	1	-	3
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-	-	1
Regents of the University of Michigan	1	-	-	-	-	-	-	-	-	6
Saint Joseph Hospital - Cancer Centers of Colorado	1	-	-	-	-	-	-	1	-	-
Salem Hospital	7	-	-	2	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	52	-	7	1	-	-	-	14	-	7
Sutter Cancer Research Consortium	51	-	-	1	1	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	13	-	-	1	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	43	-	1	2	1	-	-	11	-	15
UC Irvine Health/Chao Family Comprehensive Cancer Center	30	-	1	-	-	-	-	5	-	1
UC San Diego Moores Cancer Center	16	-	-	1	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	86	-	12	7	-	-	-	2	5	10
USC Norris Comprehensive Cancer Center LAPS	-	-	6	-	-	-	-	7	-	3
U of Alabama at Birmingham / Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	-	12
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	17	-	12
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	-	1	1	1	6	-	3
University of Kansas Cancer Center - MCA Rural MU NCORP	105	-	1	1	-	-	-	-	-	5
University of Kentucky/Markey Cancer Center	55	-	1	-	-	-	-	-	-	9
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	33	-	1	-	-	-	-	6	18	10
University of Rochester LAPS	61	-	-	6	-	-	1	-	-	14
University of Texas Health Science Center at San Antonio	-	-	2	-	-	-	-	-	-	22
University of Texas MD Anderson Cancer Center LAPS	3	-	6	-	-	-	-	6	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	4	-	-	-	-	5	-	4
Upstate Carolina Consortium Comm Oncology Research Program	41	-	3	-	-	-	-	3	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	10
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	42	-	4	1	-	-	-	13	-	5
Yale University - Yale Cancer Center LAPS	28	-	5	3	4	-	-	11	-	14
ALLIANCE	884	-	25	21	3	1	3	42	5	154
CCTG	-	-	36	-	-	-	-	-	-	-
ECOG-ACRIN	367	1	11	19	-	-	3	31	-	90
NRG	505	-	83	12	3	-	-	91	1	55
Total	3,666	3	285	118	21	2	10	417	45	838

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

[illegible]

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2414	A081801	A082002	A151216	E4512	EA5162	EA5163	EA5182	EA5221	NRGLU008	S2402
Moffitt Cancer Center	-	27	-	83	1	-	5	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	8	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	1	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	3	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	8	-	24	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	4	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	-	51	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	1	-	3	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	11	-	-	-	-	-	1	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	5	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	2	46	1	-	6	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	15	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	5	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	12	-	-	-	-	-	-	-
U of Alabama at Birmingham / D South Research Consort LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	3	1	-	1	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	24	1	-	2	1	-	-	-
University of Colorado Cancer Center LAPS	-	2	-	58	2	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	-	31	-	-	7	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	1	5	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	26	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-	-	3
University of Rochester LAPS	-	-	-	-	-	-	6	-	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	2	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	2	1	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	1	-	-	-	-
Upstate Carolina Consort Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	57	4	-	14	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	2	92	4	986	22	4	84	24	2	3	4

